Experimental Therapeutics, Molecular Targets, and Chemical Biology
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin, Melissa Ooi, Jake Delmore, Joseph Negri, Patrick Hayden, Nicolas Mitsiades, Jana Jakubikova, Sauveur-Michel Maira, Carlos Garcia-Echeverria, Robert Schlossman, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson and Constantine S. Mitsiades
Douglas W. McMillin
Melissa Ooi
Jake Delmore
Joseph Negri
Patrick Hayden
Nicolas Mitsiades
Jana Jakubikova
Sauveur-Michel Maira
Carlos Garcia-Echeverria
Robert Schlossman
Nikhil C. Munshi
Paul G. Richardson
Kenneth C. Anderson
Constantine S. Mitsiades
DOI: 10.1158/0008-5472.CAN-08-4285

This is a PDF-only article. The first page of the PDF of this article appears below.

Published OnlineFirst July 7, 2009
doi: 10.1158/0008-5472.CAN-08-4285
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin, Melissa Ooi, Jake Delmore, Joseph Negri, Patrick Hayden, Nicolas Mitsiades, Jana Jakubikova, Sauveur-Michel Maira, Carlos Garcia-Echeverria, Robert Schlossman, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson and Constantine S. Mitsiades
Cancer Res July 7 2009 DOI: 10.1158/0008-5472.CAN-08-4285
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin, Melissa Ooi, Jake Delmore, Joseph Negri, Patrick Hayden, Nicolas Mitsiades, Jana Jakubikova, Sauveur-Michel Maira, Carlos Garcia-Echeverria, Robert Schlossman, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson and Constantine S. Mitsiades
Cancer Res July 7 2009 DOI: 10.1158/0008-5472.CAN-08-4285
Jump to section
Advertisement